M&A Deal Summary |
|
|---|---|
| Date | 2023-03-02 |
| Target | Dynacure |
| Sector | Life Science |
| Buyer(s) | Flamingo Therapeutics |
| Sellers(s) | Andera Partners |
| Deal Type | Merger |
SEARCH BY
Flamingo Therapeutics is pioneering RNA-targeted therapies for oncology with state-of-the art chemistries and a clinical-stage pipeline targeting undruggable transcription factors and splice variants. Flamingo Therapeutics has a Phase II trial (PEMDA-HN) evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC). Flamingo Therapeutics is based in Leuven, Belgium.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Merger M&A Deals | 1 of 1 |
| Country: France M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 3.7B EUR |
| Size | Large |
| Type | Sector Agnostic |
Andera Partners is a private investment firm focused on several strategies. The Firm invests in life science opportunities through its BioDiscovery group. The Firm invests in Western European small to mid-sized companies (€30 to €300 million of revenue) through its Winch Capital group. Andera invests in small to mid-sized French companies (€10 to €100 million of revenue) through its Cabestan Capital team. Andera invests in €5 to €45 million of mezzanine capital to support small to mid-sized French companies. Andera Partners was established in 2001 and is headquartered in Paris.
| DEAL STATS | # |
|---|---|
| Overall | 36 of 51 |
| Sector: Life Science M&A | 6 of 9 |
| Type: Merger M&A Deals | 1 of 1 |
| Country: France M&A | 27 of 40 |
| Year: 2023 M&A | 4 of 9 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-02-09 |
Mineralys
Radnor, Pennsylvania, United States Mineralys is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the company is initially developing for the treatment of patients with uncontrolled hypertension. Mineralys was founded in 2019 and is based in Radnor, Pennsylvania. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-04-14 |
Orest
Erstein, France Orest creates and manufactures Jewellery. Orest was founded in 1963 and is based in Erstein, France. |
Sell | - |
